Ask any multi-state operator where the real headaches live, and terpene sourcing sits near the top of the list. You’re running extraction and formulation across state lines that legally can’t touch each other, each with its own rulebook, testing thresholds, and packaging demands. What works in one market becomes a compliance problem in the next.

The core question underneath all of it is deceptively simple. Do you build terpene capability in-house, buy from external suppliers, or run some blend of both? This is a make-buy-partner decision, and getting it wrong ties up capital or leaves you exposed on consistency. Here’s how to think through it.

Why Terpene Sourcing Is Harder for MSOs Than Single-State Brands

A single-state brand solves this once. An MSO solves it in every market, and the markets refuse to cooperate with each other.

Start with the obvious constraint. Cannabis-derived terpenes (CDT) can’t cross state lines. Federal law keeps cannabis products locked inside the state where they’re produced, so a beautiful CDT profile extracted in Michigan is legally useless in Arizona. You either rebuild that extraction capability in every state or you find another path.

Then layer on the regulatory patchwork. Testing thresholds, residual solvent limits, and permitted additives vary state to state. A formulation that passes in one market can fail an ingredient check in another. Your procurement team isn’t buying one product, they’re buying a moving target across a dozen jurisdictions.

And the thing your brand actually gets judged on is consistency. A consumer who loves your vape in Nevada expects the same experience in Illinois. When your terpene inputs shift by state, that promise gets fragile fast. Cost efficiency matters too, but consistency across states is usually the harder problem to solve at scale.

The Make-Buy-Partner Framework

What is the make-buy-partner framework? It’s a procurement model for deciding whether to produce something internally (make), source it from the open market (buy), or build a deeper supplier relationship that behaves like an extension of your team (partner).

For terpenes, these three paths carry very different capital, risk, and control profiles:

• Make (vertical integration): Build your own extraction and formulation capability, often per state for CDT.
• Buy (transactional): Purchase off-the-shelf terpene blends from suppliers as needed, minimal commitment.
• Partner (strategic supply): Work with a formulation partner on custom profiles, shared specs, and consistent supply that follows your brand across markets.

Most MSOs don’t land cleanly in one box. But you have to understand each on its own before you can design the blend that fits your business.

Vertical Integration: Building Extraction In-House

Vertical integration is the control play. You own the process end to end, which is exactly why it’s tempting and exactly why it’s expensive.

The upside is real. You control the profile, the quality, and the margin. For high-volume core SKUs, in-house extraction can pull cost per unit down meaningfully once you’re running at scale. You also get direct access to cannabis-derived terpenes, which some brands treat as a genuine differentiator worth building around.

Now the hard part. Capital for in-house extraction infrastructure often runs from several hundred thousand dollars into the low millions per facility, depending on equipment, throughput, and buildout. For an MSO, remember that CDT extraction usually has to be replicated in each state, so you’re not funding one facility, you’re funding several.

Timelines are the other tax. Standing up compliant extraction typically takes many months to well over a year once you account for equipment lead times, licensing, buildout, and validation. You also inherit ongoing costs: skilled operators, maintenance, QC labs, and the overhead of running a scientific operation inside a company that mostly wanted to sell great products.

Vertical integration makes the most sense when volume is high, capital is available, and terpene profile is central to your brand story. If those three aren’t all true, the math gets shaky.

Partnership: Buying From External Suppliers

Partnership flips the equation. Instead of owning the machinery, you own the relationship and the spec, and let a specialist handle production.

The advantages line up against exactly the pain points MSOs feel. There’s little to no capital outlay, so you’re not sinking millions into facilities before you’ve proven the SKU. You move faster, since a capable partner already has the equipment, the analytical chemistry, and the quality systems running. And a good partner can deliver the same formulation into every state you operate in, which directly attacks the consistency problem that vertical integration struggles with across borders.

This is where a custom formulation partner earns its keep. Working with a supplier that offers custom terpene formulation at scale means you define the profile once and get it reproduced reliably, batch after batch, rather than reverse-engineering consistency yourself in a dozen facilities.

The trade-offs are worth naming. You give up some margin, and you’re dependent on a third party for a core input. That’s why partner selection is a serious decision, not a purchasing formality. You want a supplier with real analytical rigor: GC-MS testing, cGMP manufacturing, documented sourcing, and the scientific credibility to stand behind every batch. Terpene sourcing partners with that kind of depth, like the team behind The Werc Shop and founder Dr. Jeffrey Raber, are the ones that hold up under audit and don’t leave you guessing about what’s in the bottle.

Partnership fits best when speed matters, capital is better spent elsewhere, or you need cross-state consistency without building infrastructure in every market.

The Hybrid Approach: In-House Core, Partners for Specialty

Most mature MSOs don’t pick a lane. They run both, and the split usually falls along the same line.

The logic is straightforward. Build in-house for the small number of high-volume core SKUs where scale justifies the capital and where owning the profile matters to your brand. Then partner for everything else: specialty profiles, limited runs, new-market launches, and any product where standing up dedicated extraction can’t be justified.

Here’s why that combination works so well:

1. Capital efficiency. You concentrate heavy investment on the SKUs that actually generate the volume to pay it back, instead of spreading it thin across your whole catalog.
2. Flexibility. Partners let you launch specialty and seasonal products without a facility buildout, so your catalog can move at market speed.
3. Risk balance. You’re not fully exposed to a single supplier, and you’re not carrying the full overhead of in-house production for every product line.
4. Faster market entry. Entering a new state? A partner covers you on day one while you decide whether that market ever justifies in-house extraction.

The hybrid model tends to be where scaled operators end up, because it matches capital intensity to where the volume actually is.

A Decision Matrix by Capital, Volume, and State Count

There’s no universal answer here, so use your own numbers. The three variables that move the decision most are available capital, product volume, and how many states you run. Read this as directional guidance, not a formula:

Notice the pattern. Vertical integration only pulls ahead when high volume, strong capital, and enough states line up together. Below that threshold, partnership or a partner-weighted hybrid almost always wins on capital efficiency and speed. Run this against your real per-SKU volumes before committing anyone’s budget.

Compliance Considerations for Each Model

Compliance isn’t a footnote to the sourcing decision. It often reshapes the decision entirely, so weigh it deliberately for each model.

With vertical integration, you own the full compliance burden in every state you operate. That means state-specific licensing, testing protocols, residual solvent controls, and documentation, replicated market by market. More facilities means more audit surface and more ways for a single state’s rule change to become your problem.

With partnership, much of the analytical and manufacturing compliance load shifts to your supplier, but only if that supplier is genuinely equipped to carry it. This is why partner due diligence is non-negotiable. You want documented GC-MS results, cGMP processes, transparent ingredient disclosure, and clean paperwork you can hand to a regulator without flinching. A weak partner doesn’t reduce your compliance risk, it just hides it until an audit finds it.

With the hybrid model, you’re managing two compliance systems at once: your in-house obligations plus your partner oversight. It’s more coordination, but it also lets you keep the tightest control where you have volume and lean on a vetted partner’s systems everywhere else. One point applies to every model. Whoever produces your terpenes, the testing and documentation have to be defensible, because in this industry the paperwork is the product almost as much as the terpenes are.

Choosing the Right Path for Your Operation

The MSO terpene sourcing decision comes down to matching your model to your reality. If you’re early, capital-light, or spread thin across new markets, partnership gets you consistent, compliant product without freezing millions in extraction facilities. If you’re scaled with proven high-volume SKUs, a hybrid approach lets you own the core and partner for the rest. Vertical integration earns its place only at the top of the volume and capital curve.

Whatever the mix, the partner side of the equation deserves the same scrutiny as any facility you’d build. If you’re weighing custom formulation at scale, it’s worth talking to a team that pairs custom terpene development with the analytical chemistry and cGMP standards that hold up across every state you serve. That’s the difference between a supplier and an actual partner in your supply chain.